Research output per year
Research output per year
Organisation profile
Organisation profile
Aims and objectives
Through interdisciplinary basic and translational biomedical research we wish to improve knowledge of diseases, develop new treatments and tests in order to obtain the optimal individualised treatment to patients with cancers.
Objectives: to improve quality of life, disease control and survival for adult patients with solid tumours.
Aims:
- to develop more effective cancer treatments through rational and efficient clinical and laboratory research,
- to optimize current treatments by personalizing them and increase the efficacy
- to reduce side effects.
Focus areas
Our focus areas:
- Tumour immunology Phase 1-3 clinical trials, both academically led and commercial oncology clinical trials. The portfolio of studies includes novel therapies such as vaccines and immunotherapies and first in human trials
- Radiotherapy
- Electroporation
- Biomarkers and genomic profiling
Disciplines, methods and tools
- Participation in international research networks
- First in man studies
- 60-65 active studies across the majority of oncology disease sites
- Locally developed clinical databases and eCRFs
- Gene profiling
- Bio bank for different types of cancer
- Clinical studies with translational research as a key objective
- Clinical studies with radiotherapy
- Intraperitoneal therapy
- Intratumoral therapy
- Electroporation therapy
- TACE – Trans Arterial Chemoembolization
- GMO studies
- Immunotherapies
- GMP Certified laboratory for preparation of therapeutic cellular products and evaluations/monitoring of immune responses
- Production of both T-cells and Dendritic Cells (including mRNA transfection) for clinical use
- TILS
Useful links
Fingerprint
Dive into the research topics where Oncology is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Benedetta Albieri
- Herlev and Gentofte Hospital, Center for Cancer Immune Therapy (CCIT) - Videnskabelig Assistent
Person: VIP
-
18F-FDG PET/CT assessment of metabolic tumor burden predicts survival in patients with metastatic posterior uveal melanoma
Hindso, T. G., Martinussen, T., Bjerrum, C. W., Keller, S. H., Loft, A., Sjøl, M. B., Nissen, K., Faber, C., Donia, M., Svane, I. M., Ellebaek, E., Heegaard, S., Kiilgaard, J. F. & Madsen, K., 3 Feb 2025, In: Scientific Reports. 15, 1, 4110.Research output: Contribution to journal › Journal article › Research › peer-review
-
1-year efficacy results after MR-guided risk-adapted stereotactic radiotherapy of infra-diaphragmatic oligometastases in a multicenter phase II trial
van Overeem Felter, M., Møller, P. K., Josipovic, M., Bekke, S. N., Bernchou, U., Serup-Hansen, E., Parikh, P., Kim, J., Geertsen, P., Behrens, C. P., Madsen, K., Vogelius, I. R., Topsøe, J. F., Berthelsen, A. K., Pøhl, M., Schytte, T. & Persson, G. F., 2025, In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 205, 110748.Research output: Contribution to journal › Journal article › Research › peer-review
-
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
Amaral, T., Nanz, L., Higuita, L. M. S., Ascierto, P., Berking, C., Couselo, E. M., Donia, M., Dummer, R., Gutzmer, R., Haushild, A., Jalving, M., Lee, R., Lorigan, P., Marquez-Rodas, I., Michelin, O., Nathan, P., Robert, C., Schadendorf, D., Sobczuk, P. & Flatz, L. & 2 others, , 17 Jan 2025, In: European journal of cancer (Oxford, England : 1990). 215, p. 115160 115160.Research output: Contribution to journal › Journal article › Research › peer-review